Omeprazole

All congenital malformations (majors, minors, majors and minors, or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S4447
R13163
Matok, 2012 Major malformations (according to CDC definitions) 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.11 [0.87;1.43] 67/955   6,438/109,828 6,505 955
ref
S4669
R35112
Bànhidy, 2011 Congenital abnormalities during pregnancy (anytime or not specified) excluded case control unexposed (general population or NOS) Adjustment: No Matched 1.23 [1.02;1.47] C
excluded (exposition period)
206/487   22,637/60,507 22,843 487
ref
S4408
R13165
Pasternak, 2010 Major birth defects (Exposure during First Trimester) 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 1.05 [0.79;1.40] 52/1,800   21,867/837,317 21,919 1,800
ref
S4517
R28445
Diav-Citrin, 2005 Major anomalies 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 1.09 [0.49;2.42] C 8/194   30/792 38 194
ref
S4548
R10997
Källén, 2001 Congenital malformations (ICD9 - ICD10) at least 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes 0.82 [0.50;1.34] 22/863   -/- 13 863
ref
S8548
R28405
Moretti, 2001 Major malformations at least 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No 1.36 [0.20;9.38] 2/55   2/75 4 55
ref
S4878
R12784
Ruigomez (Controls exposed to other treatment, sick), 1999 Malformations (minor and major) 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.65 [0.25;1.69] C
excluded (control group)
5/139   31/567 36 139
ref
S4877
R12737
Ruigomez (Controls unexposed NOS), 1999 Malformations (minor and major) 1st trimester retrospective cohort unexposed (general population or NOS) Adjustment: Yes 0.90 [0.40;2.40] 5/139   64/1,575 69 139
ref
S4591
R13161
Lalkin (Controls exposed to other treatment, sick), 1998 Major malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No Matched 1.71 [0.37;7.89] C
excluded (control group)
4/78   3/98 7 78
ref
S4594
R13162
Lalkin (Controls unexposed NOS), 1998 Major malformations 1st trimester prospective cohort unexposed (general population or NOS) Adjustment: No Matched 1.73 [0.31;9.76] C 4/78   2/66 6 78
ref
Total 7 studies 1.05 [0.89;1.24] 28,554 4,084
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Matok, 2012Matok, 2012 1.11[0.87; 1.43]6,50595545%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Pasternak, 2010Pasternak, 2010 1.05[0.79; 1.40]21,9191,80034%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Diav-Citrin, 2005Diav-Citrin, 2005 1.09[0.49; 2.42]381944%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Källén, 2001Källén, 2001 0.82[0.50; 1.34]1386311%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Moretti, 2001Moretti, 2001 1.36[0.20; 9.38]4551%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Ruigomez (Controls unexposed NOS), 1999Ruigomez, 1999 1 0.90[0.40; 2.40]691393%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Lalkin (Controls unexposed NOS), 1998Lalkin, 1998 2 1.73[0.31; 9.76]6781%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (7 studies) I2 = 0% 1.05[0.89; 1.24]28,5544,0840.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed NOS; 2: Controls unexposed NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.05[0.89; 1.24]28,5544,0840%NAMatok, 2012 Pasternak, 2010 Diav-Citrin, 2005 Källén, 2001 Moretti, 2001 Ruigomez (Controls unexposed NOS), 1999 Lalkin (Controls unexposed NOS), 1998 7 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.05[0.89; 1.24]28,5544,0840%NAMatok, 2012 Pasternak, 2010 Diav-Citrin, 2005 Källén, 2001 Moretti, 2001 Ruigomez (Controls unexposed NOS), 1999 Lalkin (Controls unexposed NOS), 1998 7 Tags Adjustment   - No  - No 1.20[0.61; 2.37]483270%NADiav-Citrin, 2005 Moretti, 2001 Lalkin (Controls unexposed NOS), 1998 3   - Yes  - Yes 1.04[0.88; 1.24]28,5063,7570%NAMatok, 2012 Pasternak, 2010 Källén, 2001 Ruigomez (Controls unexposed NOS), 1999 4 MatchedMatched 1.73[0.31; 9.76]678 -NALalkin (Controls unexposed NOS), 1998 1 All studiesAll studies 1.05[0.89; 1.24]28,5544,0840%NAMatok, 2012 Pasternak, 2010 Diav-Citrin, 2005 Källén, 2001 Moretti, 2001 Ruigomez (Controls unexposed NOS), 1999 Lalkin (Controls unexposed NOS), 1998 70.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-2.32.41.1780.000Matok, 2012Pasternak, 2010Diav-Citrin, 2005Källén, 2001Moretti, 2001Ruigomez (Controls unexposed NOS), 1999Lalkin (Controls unexposed NOS), 1998

Asymetry test p-value = 0.9549 (by Egger's regression)

slope=0.0443 (0.0860); intercept=0.0227 (0.3822); t=0.0595; p=0.9549

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 4591, 4878

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.05[0.89; 1.24]28,5544,0840%NAMatok, 2012 Pasternak, 2010 Diav-Citrin, 2005 Källén, 2001 Moretti, 2001 Ruigomez (Controls unexposed NOS), 1999 Lalkin (Controls unexposed NOS), 1998 7 exposed to other treatment, sick controlsexposed to other treatment, sick controls 0.87[0.36; 2.11]4321711%NARuigomez (Controls exposed to other treatment, sick), 1999 Lalkin (Controls exposed to other treatment, sick), 1998 20.510.01.0